Increased dopamine transmission in schizophrenia: relationship to illness phases

Biological Psychiatry

Volumn 46, Issue 1, 1999, Pages 56-72

  Laruelle, Marc ^a   Abi Dargham, Anissa ^a,b   Gil, Roberto ^a,b   Kegeles, Lawrence ^a   Innis, Robert ^b  

^a The New York Presbyterian Hospital   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

D2 receptors; Dopamine; Psychostimulants; Schizophrenia; SPECT

Indexed keywords

AMPHETAMINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0032987267     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00067-0     Document Type: Article

References (101)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R., Seibyl J., Bowers M., et al. Increased striatal dopamine transmission in schizophrenia Confirmation in a second cohort . Am J Psychiatry. 155:1998;761-767.
2. Abi-Dargham A., Simpson N., Kegeles L., Parsey L., Hwang D.-R., Anjilvel S., et al. PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse. 32:1999;93-109.
3. Akimoto K., Hamamura T., Kazahaya Y., Akiyama K., Otsuki S. Enhanced extracellular dopamine level may be the fundamental neuropharmacological basis of cross-behavioral sensitization between methamphetamine and cocaine - An in vivo dialysis study in freely moving rats. Brain Res. 507:1990;344-346.
4. Angrist B., Rotrosen J., Gershon S. Response to apomorphine, amphetamine and neuroleptics in schizophrenic subjects. Psychopharmacology (Berlin). 67:1980;31-38.
5. Angrist B., van Kammen D.P. CNS stimulants as a tool in the study of schizophrenia. Trends Neurosci. 7:1984;388-390.
6. Antelman S. Interchangeability of stress and amphetamine in sensitization. Science. 207:1980;329-331.
7. Booij J., Korn P., Linszen D.H., vanRoyen E.A. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med. 24:1997;674-677.
8. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., deBartolomeis A., Weinberger D.R., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations Evidence from a novel positron emission tomography method . Proc Natl Acad Sci U S A. 94:1997;2569-2574.
9. Burt D.R., Creese I., Snyder S.S. Antischizophrenic drugs Chronic treatment elevates dopamine receptors binding in brain . Science. 196:1977;326-328.
10. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1:1988;179-186.
11. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. 20:1963;140-144.
12. Carson R.E., Breier A., deBartolomeis A., Saunders R.C., Su T.P., Schmall B., et al. Quantification of amphetamine-induced changes in [C-11]raclopride binding with continuous infusion. J Cereb Blood Flow Metab. 17:1997;437-447.
13. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 19:1976;481-483.
14. Cross AJ, Crow TJ, Ferrier IN, Johnstone EC, McCreadie RM, Owen F, et al (1983): Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder. J Neural Transm (suppl 18):265-272.
15. Crow T.J. Molecular pathology of schizophrenia More than one disease process? Br Med J. 280:1980;66-68.
16. Daniel D.G., Goldberg T.E., Gibbons R.D., Weinberger D.R. Lack of a bimodal distribution of ventricular size in schizophrenia A Gaussian mixture analysis of 1056 cases and controls . Biol Psychiatry. 30:1991;887-903.
17. Dao-Castellana M.H., Paillere-Martinot M.L., Hantraye P., Attar-Levy D., Remy P., Crouzel C., et al. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res. 23:1997;167-174.
18. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia A review and reconceptualization . Am J Psychiatry. 148:1991;1474-1486.
19. Deutch A., Clark W.A., Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of the mesolimbic dopamine neurons to stress. Brain Res. 521:1990;311-315.
20. Deutch A.Y. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits Implications for schizophrenia and Parkinson's disease . J Neural Transm. 91:1993;197-221.
21. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse. 13:1993;350-356.
22. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry. 49:1992;538-544.
23. Farde L., Suhara T., Nyberg S., Karlsson P., Nakashima Y., Hietala J., et al. A PET study of [C-11]FLB 457 binding to extrastriatal D-2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology. 133:1997;396-404.
24. 11C]raclopride. Arch Gen Psychiatry. 47:1990;213-219.
25. Finlay J.M., Zigmond M.J. The effects of stress on central dopaminergic neurons Possible clinical implications . Neurochem Res. 22:1997;1387-1394.
26. Gandelman M.S., Baldwin R.M., Zoghbi S.S., Zea-Ponce Y., Innis R.B. Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers β-CIT, IBF and iomazenil . J Pharm Sci. 83:1994;1014-1019.
27. Gejman P.V., Ram A., Gelernter J., Friedman E., Cao Q., Pickar D., et al. No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA. 271:1994;204-208.
28. Grace A.A. The tonic/phasic model of dopamine system regulation Its relevance for understanding how stimulant abuse can alter basal ganglia function . Drug Alcohol Depend. 37:1995;111-129.
29. Hall H., Farde L., Sedvall G. Human dopamine receptors subtypes-in vitro binding analysis using [3H]SCH 23390 and [3H]raclopride. J Neural Transm. 73:1988;7-21.
30. Hartvig P., Torstenson R., Tedroff J., Watanabe Y., Fasth K.J., Bjurling P., et al. Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. J Neural Transm. 104:1997;329-339.
31. Hietala J., Syvalahti E. Dopamine in schizophrenia. Ann Med. 28:1996;557-561.
32. Hietala J., Syvälahti E., Vuorio K., Nagren K., Lehikoinen P., Ruotsalainen U., et al. Striatal D2 receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry. 51:1994;116-123.
33. Hietala J., Syvalahti E., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 346:1995;1130-1131.
34. Hollingshead AB (1975): Four Factor Index of Social Status. New Haven, CT: Working paper published by the author.
35. 2 receptor in non-human primates. Synapse. 10:1992;177-184.
36. Inoue O., Kobayashi K., Tsukada H., Itoh T., Langstrom B. Difference in in vivo receptor binding between [3H]N-methylspiperone and [3H]raclopride in reserpine-treated mouse brain. J Neur Transm Gen Sect. 85:1991;1-10.
37. Janowsky D.S., Davis J.M. Methylphenidate, dextroamphetamine and levamphetamine. Effects on schizophrenic symptoms. Arch Gen Psychiatry. 33:1976;304-308.
38. Kalivas P., Duffy P. The effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse. 5:1990;48-58.
39. Kalivas P.W. Neurotransmitter regulation of dopamine neurons in the ventral tegumental area. Brain Res Rev. 18:1993;75-113.
40. Kalivas P.W., Duffy P. Selective activation of dopamine transmission in the shell of the nucleus accumbens by stress. Brain Res. 675:1995;325-328.
41. Kalivas P.W., Sorg B.A., Hooks M.S. The pharmacology and neural circuitry of sensitization to psychostimulants. Behav Pharmacol. 4:1993;315-334.
42. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev. 16:1991;223-244.
43. Karreman M., Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum An effect mediated by ventral tegmental area . J Neurochem. 66:1996;589-598.
44. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13:1987;261-276.
45. Kazahaya Y., Akimoto K., Saburo O. Subchronic methamphetamine treatment enhances methamphetamine- or cocaine induced dopamine efflux in vivo. Biol Psychiatry. 25:1989;903-912.
46. Kegeles L., Zea-Ponce Y., Abi-Dargham A., Rodenhiser J., Wang T., Wess R., et al. Stability of [123I]IBZM SPECT measurement of amphetamine-induced dopamine release in healthy humans. Synapse. 31:1999;302-308.
47. Koepp M.J., Gunn R.N., Lawrence A.D., Cunningham V.J., Dagher A., Jones T., et al. Evidence for striatal dopamine release during a video game. Nature. 393:1998;266-268.
48. 3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors. Eur J Pharmacol. 72:1981;397-402.
49. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
50. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med. 42:1998;211-221.
51. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., De Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc Natl Acad Sci U S A. 93:1996;9235-9240.
52. Laruelle M., Abi-Dargham A., van Dyck C.H., Rosenblatt W., Zea-Ponce Y., Zoghbi S.S., et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 36:1995;1182-1190.
53. Laruelle M., DSouza C.D., Baldwin R.M., Abi-Dargham A., Kanes S.J., Fingado C.L., et al. Imaging D-2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology. 17:1997;162-174.
54. Laruelle M., Iyer R.N., Al-Tikriti M.S., Zea-Ponce Y., Malison R., Zoghbi S.S., et al. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse. 25:1997;1-14.
55. Lawrie S.M., Abukmeil S.S. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry. 172:1998;110-120.
56. 3H-apomorphine in schizophrenic brains. Nature. 274:1978;897-900.
57. Lidsky T.I. Reevaluation of the mesolimbic hypothesis of antipsychotic drug action. Schizophr Bull. 21:1995;67-74.
58. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 91:1987;415-433.
59. Lieberman J.A., Kane J.M., Gadaleta D., Brenner R., Lesser M.S., Kinon B. Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry. 141:1984;633-638.
60. Lieberman J.A., Kane J.M., Sarantakos S., Gadaleta D., Woerner M., Alvir J., et al. Prediction of relapse in schizophrenia. Arch Gen Psychiatry. 44:1987;597-603.
61. Lieberman J.A., Kinon B.L., Loebel A.D. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull. 16:1990;97-110.
62. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia Deficits and dysfunction in neuronal regulation and plasticity . Neuropsychopharmacology. 17:1997;205-229.
63. 18F]N-methylspiroperidol binding in the basal ganglia Comparison of simulations and experimental results from PET studies in baboons . Synapse. 9:1991;195-207.
64. Mai J.C., Assheuer J., Paxinos G. Atlas of the Human Brain. 1997;Academic Press, San Diego, CA.
65. Mathe J.M., Nomikos G.G., Schilstrom B., Svensson T.H. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res. 51:1998;583-592.
66. Miller D.W., Abercrombie E.D. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull. 40:1996;57-62.
67. Mukherjee J., Yang Z.Y., Lew R., Brown T., Kronmal S., Cooper M.D., et al. Evaluation of D-amphetamine effects on the binding of dopamine D-2 receptor radioligand, F-18-fallypride in nonhuman primates using positron emission tomography. Synapse. 27:1997;1-13.
68. Nelson M.D., Saykin A.J., Flashman L.A., Riordan H.J. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging A meta-analytic study . Arch Gen Psychiatry. 55:1998;433-440.
69. O'Donnell P., Grace A.A. Dysfunctions in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr Bull. 24:1998;267-283.
70. Owen F., Cross A.J., Crow T.J., Longden A., Poulter M., Riley G.J. Increased dopamine-receptor sensitivity in schizophrenia. Lancet. ii:1978;223-226.
71. Patrick S.L., Thompson T.L., Walker J.M., Patrik R.L. Concomitant sensitization of amphetamine-induced behavioral stimulation and in vivo dopamine release from rat caudate nucleus. Brain Res. 538:1991;343-346.
72. Paulson P.E., Robinson T.E. Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum A microdialysis study in behaving rats . Synapse. 19:1995;56-65.
73. Pettit H.O., Pan H.T., Parsons L.H., Justice J.B.J. Extracellular concentration of cocaine and dopamine are enhanced during chronic cocaine administration. J Neurochem. 55:1990;798-804.
74. Pilowsky L.S., Costa D.C., Ell P.J., Verhoeff N.P.L.G., Murray R.M., Kerwin R.W. D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An I-123-IBZM single photon emission computerized tomography study. Br J Psychiatry. 164:1994;16-26.
75. Pycock C.J., Kerwin R.W., Carter C.J. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 286:1980;74-77.
76. Reith J., Benkelfat C., Sherwin A., Yasuhara Y., Kuwabara H., Andermann F., et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A. 91:1994;11651-11654.
77. Roberts A.C., Desalvia M.A., Wilkinson L.S., Collins P., Muir J.L., Everitt B.J., et al. 6-hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin card sort test Possible interactions with subcortical dopamine . J Neurosci. 14:1994;2531-2544.
78. Robinson P.H., Jurson P.A., Bennet J.A., Bentgen K.M. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine A microdialysis study in freely moving rats . Brain Res. 462:1988;211-222.
79. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration A review and evaluation of animal models of amphetamine psychosis . Brain Res Review. 11:1986;157-198.
80. Ross S.B. Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J Neurochem. 56:1991;22-29.
81. Ross S.B., Jackson D.M. Kinetic properties of the in vivo accumulation of the dopamine D-2 receptor antagonist raclopride in the mouse brain in vivo. Naunyn Schmiedeberg Arch Pharmacol. 340:1989;6-12.
82. 3H](-)-N-n-propylnorapomorphine in the mouse brain. Naunyn Schmiedeberg Arch Pharmacol. 340:1989;13-20.
83. Sanfilipo M., Wolkin A., Angrist B., van Kammen D.P., Duncan E., Wieland S., et al. Amphetamine and negative symptoms of schizophrenia. Psychopharmacology (Berlin). 123:1996;211-214.
84. Saunders R.C., Kolachana B.S., Bachevalier J., Weinberger D.R. Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine. Nature. 393:1998;169-171.
85. Schooler N.R., Keith S.J., Severe J.B., Matthews S.M., Bellack A.S., Glick I.D., et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry. 54:1997;453-463.
86. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1:1987;133-152.
87. Seeman P., Bzowej N.H., Guan H.C., Bergeron C., Reynolds G.P., Bird E.D., Riederer P., et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology. 1:1987;5-15.
88. 3H]raclopride Implications for positron emission tomography of the human brain . Synapse. 3:1989;96-97.
89. Seeman P., Lee T. Antipsychotic drugs Direct correlation between clinical potency and presynaptic action on dopamine neurons . Science. 188:1975;1217-1219.
90. Seeman P., Niznik H.B., Guan H.C., Booth G., Ulpian C. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci U S A. 86:1989;10156-10160.
91. 2 dopamine receptor . J Biol Chem. 257:1982;6351-6361.
92. Svensson T.H., Tung C.S. Local cooling of pre-frontal cortex induces pace-maker-like firing of dopamine neurons in rat ventral tegumental area in vivo. Acta Physiol Scand. 136:1989;135-136.
93. Van der Werf J.F., Sebens J.B., Vaalburg W., Korf J. In vivo binding of N-n-propylnorapomorphine in the rat brain Regional localization, quantification in striatum and lack of correlation with dopamine metabolism . Eur J Pharmacol. 87:1986;259-270.
94. van Kammen D.P., Bunney W.E. Jr, Docherty J.P., Marder S.R., Ebert M.H., Rosenblatt J.E., et al. D-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am J Psychiatry. 139:1982;991-997.
95. van Kammen D.P., Murphy D.L. Attenuation of the euphoriant and activating effects of D- and L-amphetamine by lithium carbonate treatment. Psychopharmacologia (Berlin). 44:1975;215-224.
96. 11C]raclopride in the human brain. Synapse. 16:1994;255-262.
97. Weinberger D.R. Implications of the normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44:1987;660-669.
98. Willner P. The dopamine hypothesis of schizophrenia Current status, future prospects . Int Clin Psychopharmacol. 12:1997;297-308.
99. Wolkin A., Sanfilipo M., Angrist B., Duncan E., Wieland S., Wolf A.P., et al. Acute D-amphetamine challenge in schizophrenia Effects on cerebral glucose utilization and clinical symptomatology . Biol Psychiatry. 36:1994;317-325.
100. 2 dopamine receptors in drug-naive schizophrenics. Science. 234:1986;1558-1563.
101. 3H]raclopride binding in the rat brain. Synapse. 9:1991;188-194.